At CD BioSciences, our Blog & Insights section serves as an accessible gateway to expert knowledge, emerging trends, and critical evaluations relevant to human herpesvirus (HHV) research and drug development. As a trusted partner for biotechnology companies, pharmaceutical innovators, and academic researchers, we curate original commentary and reviews that bridge current literature, translational science, and applied preclinical strategies.
Our featured blog articles cover a range of high-value topics—from the implications of herpesvirus in neurodegeneration to the evolving role of helicase-primase inhibitors in antiviral therapy. We spotlight the interplay between oncolytic HSV and immunotherapies, highlight considerations in preclinical model selection for HHV latency, and interpret key findings from landmark clinical trials such as MASTERKEY-265 (KEYNOTE-034). Each article is written with scientific rigor and editorial clarity to meet the expectations of professionals navigating the complexities of HHV biology and therapeutic innovation.
This section complements our Resources hub by translating scientific developments into strategic insights—empowering our clients to make informed decisions in pipeline planning, assay design, or preclinical investment.
Explore our insights to stay ahead in HHV research and preclinical development.
The Alzheimer's-Herpes Link: What Does the Latest Science Say and What Does It Mean for Drug Developers?
Beyond the Polymerase: Why Helicase-Primase Inhibitors are the Next Frontier in HSV Treatment
Choosing the Right Preclinical Model for HHV Latency: A Comparative Guide
Oncolytic HSV and Immunotherapy: Reviewing the Results of the MASTERKEY-265 (KEYNOTE-034) Trial